Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

National Institutes of Health Clinical Center, Bethesda, Maryland